351
ANTI-GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR AUTOANTIBODIES ARE ASSOCIATED WITH DEVELOPMENT OF COMPLICATIONS IN RECENTLY DIAGNOSED CROHN’S DISEASE PATIENTS
Date
May 7, 2023
Explore related products in the following collection:
Tracks
Related Products
ILEOCECAL RESECTION FOR RECENTLY DIAGNOSED ILEOCECAL CROHN’S DISEASE IS ASSOCIATED WITH IMPROVED LONG-TERM OUTCOMES COMPARED TO ANTI-TUMOR NECROSIS FACTOR THERAPY: A POPULATION-BASED STUDY
BACKGROUND: Prevention of postoperative recurrence (POR) in Crohn’s disease (CD) after ileo-colonic (IC) resection is still a highly debated topic. Prophylactic immunosuppression after surgery is currently recommended in presence of at least one clinical risk factor (RF)…
INFLIXIMAB CLEARANCE IN RELATION TO DISEASE ACTIVITY DURING INDUCTION AND MAINTENANCE THERAPY OF ACUTE SEVERE AND AMBULATORY PEDIATRIC ULCERATIVE COLITIS
BACKGROUND: The low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet, which restricts FODMAP intake, currently is used as a treatment for pain-related disorders of gut-brain interaction (DGBI)…
AGA Food Intolerances, Allergy and Sensitivities
SOCIETY: AGA
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…